Jing Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jing Yang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Baohui Hong
Department of Pharmacy, The Second Hospital of Sanming, Sanming, China
2 shared publications - Caiyun Zheng
Department of Pharmacy, Fuqing City Hospital Affiliated to Fujian Medical University, Fuzhou, China
2 shared publications - Hengfen Dai
Affiliated Fuzhou First Hospital of Fujian Medical University, Fuzhou, China
2 shared publications - Meimei Lin
Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
2 shared publications - Shunmin Huang
Department of Pharmacy Fujian Medical University Union Hospital Fuzhou China
2 shared publications - Jianhui Yang
Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen University, No.10, Zhenhai Road, Siming District, Xiamen, Xiamen, CN
1 shared publication
Latest Publications
- Open Access
- 7 July 2023
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Development and Validation of a Clinical Risk Score to Predict Immune-mediated Liver Injury Caused by Sintilimab: Assessed for Causality Using Updated RUCAM
Immune-mediated liver injury is a fatal side effect of sintilimab. This study aimed to shed light on the associated risk factors and characteristics of this adverse event.
- 7 July 2023
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Open AccessDevelopment and Validation of a Clinical Risk Score to Predict Immune-mediated Liver Injury Caused by Sintilimab: Assessed for Causality Using Updated RUCAM
Immune-mediated liver injury is a fatal side effect of sintilimab. This study aimed to shed light on the associated risk factors and characteristics of this adverse event.
- Open Access
- 20 February 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (3) , e0063
Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known
Export Background: This systematic review and network meta-analysis aimed to provide a complete hepatotoxicity profile, hepatotoxicity spectrum, and safety ranking of immune checkpoint inhibitor drugs for cancer treatment. Methods: PubMed, Embase, Scopus, CINAHL, Web of Science, psycINFO, Cochrane Library, and ClinicalTrials.gov. websites were searched, and a manual search of relevant reviews and trials up to January 1, 2022, was undertaken. Head-to-head III randomized controlled trials comparing any 2 or 3 of the following treatments or different doses of the same immune checkpoint inhibitor drug were included: programmed death 1 (PD-1), programmed death ligand 1, and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) inhibitors and conventional therapy. We included 106 randomized trials (n=164,782) containing 17 treatment arms. Results: The overall incidence of hepatotoxicity was 4.06%. The rate of fatal liver adverse events was 0.07%. The programmed death ligand 1 inhibitor+targeted therapy drug+chemotherapy group had the highest risk of treatment-related increases in all-grade alanine aminotransferase and aspartate aminotransferase levels, and the differences were significant. For immune-related hepatotoxicity, no significant difference was found between PD-1 and CTLA-4 inhibitors for all-grade hepatotoxicity; however, CTLA-4 inhibitors were associated with a higher risk of grade 3–5 hepatotoxicity than PD-1 inhibitors. Conclusions: The highest incidence of hepatotoxicity and fatality was observed with triple therapy. The overall incidence of hepatotoxicity was similar between different dual regimens. For immune checkpoint inhibitor monotherapy, the overall risk of immune-mediated hepatotoxicity related to CTLA-4 inhibitors did not differ significantly from that of PD-1 inhibitors. There was no direct relationship between the risk of liver injury and drug dose, whether monotherapy or combination therapy was used.
- 20 February 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (3) , e0063
Open AccessHepatotoxicity of immune checkpoint inhibitors: What is Currently Known
Export Background: This systematic review and network meta-analysis aimed to provide a complete hepatotoxicity profile, hepatotoxicity spectrum, and safety ranking of immune checkpoint inhibitor drugs for cancer treatment. Methods: PubMed, Embase, Scopus, CINAHL, Web of Science, psycINFO, Cochrane Library, and ClinicalTrials.gov. websites were searched, and a manual search of relevant reviews and trials up to January 1, 2022, was undertaken. Head-to-head III randomized controlled trials comparing any 2 or 3 of the following treatments or different doses of the same immune checkpoint inhibitor drug were included: programmed death 1 (PD-1), programmed death ligand 1, and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) inhibitors and conventional therapy. We included 106 randomized trials (n=164,782) containing 17 treatment arms. Results: The overall incidence of hepatotoxicity was 4.06%. The rate of fatal liver adverse events was 0.07%. The programmed death ligand 1 inhibitor+targeted therapy drug+chemotherapy group had the highest risk of treatment-related increases in all-grade alanine aminotransferase and aspartate aminotransferase levels, and the differences were significant. For immune-related hepatotoxicity, no significant difference was found between PD-1 and CTLA-4 inhibitors for all-grade hepatotoxicity; however, CTLA-4 inhibitors were associated with a higher risk of grade 3–5 hepatotoxicity than PD-1 inhibitors. Conclusions: The highest incidence of hepatotoxicity and fatality was observed with triple therapy. The overall incidence of hepatotoxicity was similar between different dual regimens. For immune checkpoint inhibitor monotherapy, the overall risk of immune-mediated hepatotoxicity related to CTLA-4 inhibitors did not differ significantly from that of PD-1 inhibitors. There was no direct relationship between the risk of liver injury and drug dose, whether monotherapy or combination therapy was used.
- Open Access
- 11 August 2021
- Published by JMIR Publications Inc. in JMIR Formative Research
Design of Cancer Pain Management App Modules: Using a Modified Delphi Process (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Cancer pain is a significant public health issue. Mobile health offers improved and cost-effective care to people with cancer pain. However, the efficiency of engagement strategies and modules of this technology need to be reviewed and standardized according to expert perspectives. The use of applications (apps) for cancer pain management has increased over recent years. However, evidence regarding the efficacy and safety of these apps remains lacking. This study used the modified Delphi process on the design of cancer pain management apps. Objective: The study aimed to design the most agreed-upon modules for cancer pain management mobile apps. Methods: This study recruited experts in the domain of cancer pain management and applied a modified Delphi method to design the most relevant app modules. We used the positive coefficient and authority of expert indexes, such as the degree of coordination with expert opinions and other modules to test the reliability of the consultation. Cronbach’s α coefficient, content validity index (CVI), were used for data analysis. Results: A total of 23 experts with a mean age of 42.3 years (SD 5.7) consented to participate in the study. All of them had worked more than 10 years in the cancer pain management field. Overall, five app modules were generated. The Cronbach’s a coefficient was 0.81 for the overall scale.The scale-level CVI was 0.78. Conclusions: This study is the first in China to recruit a local panel of experts from the cancer pain management field. We used an iterative process to combine the experts’ opinions into a group consensus. The results of this study could benefit developers of health apps and inform future decision making on cancer pain management.
- 11 August 2021
- Published by JMIR Publications Inc. in JMIR Formative Research
Open AccessDesign of Cancer Pain Management App Modules: Using a Modified Delphi Process (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Cancer pain is a significant public health issue. Mobile health offers improved and cost-effective care to people with cancer pain. However, the efficiency of engagement strategies and modules of this technology need to be reviewed and standardized according to expert perspectives. The use of applications (apps) for cancer pain management has increased over recent years. However, evidence regarding the efficacy and safety of these apps remains lacking. This study used the modified Delphi process on the design of cancer pain management apps. Objective: The study aimed to design the most agreed-upon modules for cancer pain management mobile apps. Methods: This study recruited experts in the domain of cancer pain management and applied a modified Delphi method to design the most relevant app modules. We used the positive coefficient and authority of expert indexes, such as the degree of coordination with expert opinions and other modules to test the reliability of the consultation. Cronbach’s α coefficient, content validity index (CVI), were used for data analysis. Results: A total of 23 experts with a mean age of 42.3 years (SD 5.7) consented to participate in the study. All of them had worked more than 10 years in the cancer pain management field. Overall, five app modules were generated. The Cronbach’s a coefficient was 0.81 for the overall scale.The scale-level CVI was 0.78. Conclusions: This study is the first in China to recruit a local panel of experts from the cancer pain management field. We used an iterative process to combine the experts’ opinions into a group consensus. The results of this study could benefit developers of health apps and inform future decision making on cancer pain management.